A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Meso Scale Diagnostics
- Genentech
- Merck KGaA
- GlaxoSmithKline
- Exelixis
- Merck
- Les Laboratories Pierre Fabre
- Bristol-Myers Squibb
- Roche
- Novartis
This publication has 28 references indexed in Scilit: